Arrowhead Pharmaceuticals is a biopharmaceutical company developing targeted RNAi therapeutics.
Targeting Innovation
Arrowhead Pharmaceuticals develops novel drugs to treat intractable diseases by silencing the genes that cause them. Using the broadest portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. Arrowhead’s most advanced drug candidate in clinical development is ARC-520, which is designed to treat chronic hepatitis B infection by inhibiting the production of all HBV gene products. The goal is to reverse the immune suppression that prevents the body from controlling the virus and clearing the disease. Arrowhead’s second clinical candidate is ARC-AAT, a treatment for a rare liver disease associated with a genetic disorder that causes alpha-1 antitrypsin deficiency.
Lead Products
ARC-520 is an RNAi-based therapeutic designed to treat chronic hepatitis B virus (HBV) infection. It is the first clinical-stage drug candidate from Arrowhead’s Dynamic Polyconjugate® delivery platform. It is designed to treat chronic HBV infection by reducing the expression and release of new viral particles and key viral proteins with the goal of achieving a functional cure for HBV.
ARC-AAT is a novel unlocked nucleobase analog (UNA)-containing RNAi-based therapeutic for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disease that can severely damage the liver and lungs of affected individuals. The goal of treatment with ARC-AAT is to reduce the production of the mutant Z-AAT protein to prevent and potentially reverse accumulation-related liver injury and fibrosis.
The companys pre-clinical stage drug candidates include ARC-521, an RNAi-based therapeutic for the treatment of chronic hepatitis B virus; ARC-F12, an RNAi-based therapeutic to treat hereditary angioedema and thromboembolic diseases; ARC-HIF2, an RNAi-based therapeutic to treat renal cell carcinoma; and ARC-LPA, an RNAi-based therapeutic for the treatment of cardiovascular diseases. It also holds patents related to Adipotide for the treatment of obesity and related metabolic disorders. The company has research collaboration and license agreement with Shire AG to develop and commercialize targeted peptide-drug conjugates.
Platform Delivery Technology
The Dynamic Polyconjugate (DPC®) platform is an RNAi delivery system that has been demonstrated to preferentially deliver to hepatocytes, induce efficient endosomal escape, promote high levels of gene knockdown in multiple animal models, and appears to be well tolerated using a variety of RNAi trigger molecules. It is a modular system that can be optimized on a target-by-target basis and may be targeted in the future to address multiple organ systems and cell types.
Pipeline Development Strategy
Arrowhead’s internal drug pipeline is intended to drive value directly through the clinical development of novel therapeutics and to provide proof of concept for our platform technologies. In addition to our two lead product candidates, ARC-520 and ARC-AAT, we intend to nominate additional clinical candidates that utilize the DPC delivery system. Our core areas of focus for expanding our internal pipeline of RNAi therapeutics are: (1) develop intravenous (IV) administered liver-targeted candidates; (2) develop subcutaneously administered liver-targeted candidates; and (3) explore extra-hepatic targets, including oncology.
After some brief discussion of LEAPs, etc. on YMB, I decided to do a little research and educate myself. I want to post here to avoid excess flaming and maybe get some reasonable responses from y'all. I'm not experienced with trading or options, but I am an engineer so I understand math a little bit. I will be using the recently discussed ARWR options numbers for this post, for the most part.
Assumptions:
1. I believe strongly in Arrowhead; I believe it will be successful. Not sure HOW successful, but somewhere between VERY and OF BIBLICAL PROPORTIONS. Therefore, I want to own more shares.
2. I don't have a lot of extra money at the moment. I have some. I will have more extra money over the next 8 months.
The January 2017 options are about $0.20 each (not sure exactly how to read that cost on Yahoo Finance), for a $15 strike. So if the PPS is over 15, I can buy those options for 15 per share. So that would cost me 0.20 per share now, then 15 more next January, plus fees.
The January 2018 options are $2.00 each with a $10 strike. So I can buy these options now for $2 each, and pay $10 per share in Jan 2018 if the PPS is over $10? So total of $12 per share plus fees. But more up front.
OR, I can just buy shares now at ~$6 and keep adding as I get more money.
Is this pretty much the long and the short of it? Any advice or comments?
Post by Think2Succeed on May 3, 2016 11:13:39 GMT -5
Yes @qbeing that's exactly how it works. I'll add two comments though:
1. If you buy the Jan 2017 calls with a strike of $15 for $0.20 each contract (a contract gives you the right to buy 100 shares) AND the PPS at expiration is under $15 then you lose your entire initial investment of $0.20/contract bought.
2. The good news is that if the share price appreciates ..let's say to around $13 in November and you think the share price won't rich $15 by Jan 2017 you can always sell your calls (contracts) at any time without having to wait for the expiration date. If ARWR would trade for $13 in November you'd probably get around $1 per contract for your initial $0.20/contract investment...a super nice 5x ROI without having to worry about the PPS getting to $15 anymore.
1. So you are telling me that in the above scenario, $0.20 will give me control of 100 shares? That's crazy. So for $2000 I can have options on 1 million shares? There must be some upper limit.
2. Can I choose to sell just some of my contracts? Can I allow a portion of my options to expire unused? For example, if I get 10 contracts (1,000 shares) with $15 strike next January, and when I get there (and share price is over $15), maybe I don't have $15,000 available. Maybe I can only purchase $7,500.
Post by Think2Succeed on May 4, 2016 7:23:18 GMT -5
1. Yes $0.20 x 100 gives you control of 100 shares BUT you also must pay $15/share to own them....you can only convert your contracts into shares after you pay the price you agreed to initially when you bought the options...that's why you need a share price >$15.20 by expiration to make this a profitable transaction for you. There is no upper limit...$2000 gives you control of 10 000 shares (2000/$0.20 = 10 000) .meaning every $1 above $15 means $10 000 in profits for you...how cool is that, right ?. That's why I also own 90 Jan 2017 calls (different strikes) that gives me control of 9000 more shares.
2. Yes to both questions. You can sell only some of your contracts and you can convert into shares the rest...in either case you still make a nice profit (your contracts aren't left unused because you can just sell them for a much better price than the one you paid for them without the need to convert them). That's why they're called options...because you have a lot of options with them.
PS: Edited..sorry i made a mistake initially (i forgot to multiply by 100 to get the contract's price)
There is tax consequences on this trade. You are holding this transaction under 1 year, the profits will be taxed as regular income. I am not a CPA you need to talk to one before selling and/or converting options to shares. A $.20 option costs $20.00 plus fees. Options can be sold or exercised at any time up to the expiration date.